Eli Lilly Expands Early Access to Retatrutide Following Patient Advocacy Eli Lilly has confirmed it will allow a broader range of patients to apply for early access to its unapproved obesity drug, retatrutide. The decision follows a report by STAT regarding a 79-year-old patient who previously received special access to the medication. The pharmaceutical company … Read more
Precision Oncology Advances: Intratumoral Immunotherapy and the Future of Melanoma Treatment A New Approach to Melanoma: Direct Injection for Targeted Immune Response View this post on Instagram about French Health Agency From Instagram — related to French Health Agency Researchers at Gustave Roussy have been pioneering a novel approach to treating advanced melanoma, focusing on … Read more
AI-Powered Drug Discovery: Lilly and Insilico Medicine Forge a $2.75 Billion Partnership The pharmaceutical landscape is undergoing a seismic shift, driven by the integration of artificial intelligence (AI) into drug discovery. A recent collaboration between Eli Lilly and Insilico Medicine, valued at up to $2.75 billion, exemplifies this trend. The deal, announced on March 29, … Read more
China’s Biotech Rise: A Global Reshaping of Drug Development The biotech landscape is undergoing a significant shift, with China rapidly emerging as a dominant force. This ascent is not happening in isolation; it’s intertwined with challenges to global collaboration and a wave of consolidation within the industry. NIH Restrictions and the Impact on Global Research … Read more
The Shifting Sands of Patent Battles: AI, First-to-File and the Future of Innovation The US patent system, a cornerstone of innovation, is facing increasing scrutiny, particularly as it relates to rapidly evolving fields like artificial intelligence. Recent proposals from the United States Patent and Trademark Office (USPTO) to alter how patents are challenged are raising … Read more
Lilly’s Retatrutide: A New Era in Diabetes and Weight Management? Eli Lilly’s investigational drug, retatrutide, is generating significant buzz after demonstrating impressive results in a late-stage trial for Type 2 diabetes. The findings, released today, suggest a potential breakthrough in managing both blood sugar and weight – a historically challenging combination for individuals with the … Read more
The Growing Conflict Between Corporate Medicine and Independent Practice The healthcare landscape is witnessing a renewed clash between large hospital systems and independent physician groups, exemplified by a current battle in Oregon. This dispute, as reported by Tara Bannow, centers on the state’s recently revised ban on corporate medicine – a law designed to protect … Read more
FDA Vaccine Chief’s Exit Signals a Potential Shift in Regulatory Scrutiny The recent departure of Dr. Vinay Prasad, the Food and Drug Administration’s (FDA) vaccine chief, marks a potentially significant moment for the agency and the pharmaceutical industry. Prasad’s second exit from the FDA, confirmed on March 6, 2026, follows a period of controversial decisions … Read more
FDA Vaccine Chief Prasad’s Second Exit: A Sign of Shifting Regulatory Landscape? WASHINGTON — Vinay Prasad, a controversial figure at the Food and Drug Administration, is leaving the agency for a second time, marking the latest in a series of dramatic departures from the FDA. Prasad, director of the Center for Biologics Evaluation and Research … Read more
Moderna Reaches $2.25 Billion Settlement in COVID-19 Vaccine Patent Dispute Moderna has agreed to a substantial settlement, potentially reaching $2.25 billion, to resolve a patent conflict with Roivant Sciences and its subsidiaries, Genevant Sciences and Arbutus Biopharma. The dispute centered on the technology used to deliver Moderna’s mRNA-based COVID-19 vaccine. The Core of the Dispute: … Read more